In terms of clinical research, some articles have suggested that MM patients have higher levels of IL-17 than normal controls and higher levels of IL-17A in advanced stages (19), and the increased ratio of IL-17:IL-27 in the bone marrow had worse progression-free survival (PFS) period (24). Here, IL17A is linked to Miyoshi myopathy.